Comparability, bridging studies, and regulatory considerations: making the move to AAV producer cell lines

PREVIEW: Hover over the large cell for an interactive sneak peek.

Is your AAV manufacturing process ready for producer cell lines?

Switching from transient transfection to a stable producer cell line promises lower costs, greater consistency, and easier scale-up.

This infographic distills a recent panel discussion with four experts in platform technologies, R&D, and regulatory affairs. Read to find out:

✓

When to make the switch, and how disruptive it is at each stage of development

✓

Why the cell line, not the plasmid, becomes your most critical starting material

✓

Whether a producer cell line switch triggers a clinical bridging study, and the three factors that shape how much data regulators expect

✓

Which assumptions about your downstream process may not hold

Explore the free interactive infographic below, or listen to the podcast here.